Thrombosis and COVID-19

Last Week in Medicine

Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

3+ y ago 17:09

MP3•에피소드 홈

Today I do a quick review of the COVID-19 thrombosis literature from the last year to try to answer some of the following questions: Why does COVID-19 cause thrombosis? How many patients with COVID-19 develop thrombotic complications? Why do patients with COVID-19 on VTE prophylaxis still develop blood clots? Should we use intermediate dosing of anticoagulation for prophylaxis? What about full dose therapeutic anticoagulation (no!) What do the guidelines say?
Lots of papers:
JAMA IM Review
Autopsy Findings and VTE in Patients with COVID-19
Klok et al
Helms et al
Shah et al
Piazza et al
Porfidia et al
Kunutsor et al
Dutt et al
Stessel et al
Paranjpe et al
Fraisse et al
Musoke et al
Patel et al
ISTH Guidelines
ACCP Guidelines
Take home points:

COVID-19 is associated with an elevated risk of thrombosis.
Observational data suggests that ICU patients are likely to develop thrombotic complications even on standard VTE prophylaxis. This number seems to be round 25%. Ward patients are also at higher risk (around 8-9%).
Critically ill patients commonly develop heparin resistance, and this may partially explain why some patients with COVID develop thrombotic complications despite prophylaxis.
Some have suggested intermediate dosing of anticoagulation for prophylaxis, but there are no randomized controlled trials published at this time, and observational data are limited.
Some have suggested therapeutic dosing of anticoagulation for critically ill patients, but observational data show high rates of bleeding and other complications, and the three largest randomized controlled trials have stopped enrolling critically ill patients into the therapeutic anticoagulation arm due to safety concerns and futility.
Some have suggested targeting a certain anti-Xa activity level, but no one really knows what that should be, and there aren’t any guidelines recommending it.
ISTH and ACCP have both put out guidelines which are overall pretty similar.
Make sure your patient has VTE prophylaxis, preferably a LMWH, and keep an eye out for thrombotic complications so you can treat them in a timely manner.

Music from https://filmmusic.io
"Sneaky Snitch" by Kevin MacLeod (https://incompetech.com)
License: CC BY (http://creativecommons.org/licenses/by/4.0/)

57 에피소드

#Fitness #Medicine #Stephen Jenkins, MD, Austin Rupp, MD #Austin Rupp #Internal Medicine #Medical Journals #Research Articles #Guidelines #Alternative Health #Mental Health